uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

Insiders have been trading these 5 stocks: (($QURE)), (($TARA)), (($ABEO)), (($CBRS)) and (($VRSN)). Here is a breakdown of their recent trades and...

uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS) and uniQure (QURE) with...

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

uniQure ( ($QURE) ) has provided an update. On June 23, 2026, uniQure N.V. priced an upsized underwritten public offering of 4,945,055 ordinary sha...

uniQure Completes Upsized Public Equity Offering for Growth

In a report released yesterday, Eliana Merle from Barclays upgraded uniQure to a Buy, with a price target of $65.00. Merle covers the Healthcare se...

Positive Report for uniQure (QURE) from Barclays

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ClearPoint Neuro (CLPT) and uniQure (QURE) with bull...

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on uniQure. The company’s shares closed yesterday at $48.16. Acc...

TD Cowen Sticks to Their Buy Rating for uniQure (QURE)

UniQure stock was up on Wednesday after the company announced an updated from the FDA.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	QURE	$41.10	-3.59%	1.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QURE	$41.10	-3.6%	1.46M
3
4
5
6

QURE

QURE

Get uniQure N.V. Data in Excel

Get uniQure N.V. Data in Excel